Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$126.27 USD

126.27
146,545

+1.85 (1.49%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Paragon 28's Shares Rise After Launch of Phantom Fibula Nail System

FNA unveils Phantom Fibula Nail System, a less invasive, next-gen solution for ankle fractures, offering enhanced precision, stability and better patient outcomes.

Abbott Stock Gains on Q3 Earnings Beat, Margins Expand

ABT delivers a strong underlying base business performance in the third quarter of 2024.

Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan

CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.

Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.

AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device

ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.

GE HealthCare's Shares Rise After the Launch of Versana Premier

GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.

Neogen Q1 Earnings Miss Estimates, Margins Crash

NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.

All You Need to Know About Addus HomeCare (ADUS) Rating Upgrade to Buy

Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADUS or USPH: Which Is the Better Value Stock Right Now?

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare

Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.

Sumit Singh headshot

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.

Addus HomeCare (ADUS) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 12.50% and 1.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

ADUS vs. CHE: Which Stock Is the Better Value Option?

ADUS vs. CHE: Which Stock Is the Better Value Option?

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare

Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?

Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.

Encompass Health (EHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?

Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.

Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?

Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant

DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.

Nalak Das headshot

Top 5 Outpatient and Home Healthcare Stocks for Solid Returns

We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.

Compared to Estimates, Addus HomeCare (ADUS) Q1 Earnings: A Look at Key Metrics

The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ADUS or USPH: Which Is the Better Value Stock Right Now?

ADUS vs. USPH: Which Stock Is the Better Value Option?